Keywords: Gillea, HIV drugs, Developing countries, Ranbaxy, Mylan, Matrix, Strides Arcolabs, Hetero, MSF, Reservations

Ranbaxy and Mylan unit to make and market three Gilead HIV drugs in developing countries

Article | 13 July 2011

Print This

India’s largest drugmaker Ranbaxy Laboratories (RANB: BO) says it has entered into an in-licensing agreement with US biotech ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in